Antidepressants

Most antidepressants were either ineffective or lacked evidence for effectiveness when used for the treatment of certain chronic pain conditions, suggesting “a more nuanced approach is needed,” researchers wrote in BMJ.

Two companies have partnered on a clinical depression support tool that predicts the effectiveness of antidepression treatments.

Antidepressants desvenlafaxine, paroxetine, venlafaxine and vortioxetine were found to have reasonable acceptability, efficacy and tolerability in the treatment of adults with stable major depressive disorder.

Adults with type 2 diabetes or a sleep disorder have an increased risk for depression compared with those with neither condition, according to data published in the Journal of Diabetes and Its Complications.

Conveying the efficacy of pain management approaches may help rheumatologists better manage their patients’ expectations and long-term pain relief, noted a presenter at the 2021 Congress of Clinical Rheumatology-East.

Antidepressants are mostly ineffective for treating back pain, but may be beneficial for osteoarthritis and sciatica, according to data published in BMJ.

A recent study demonstrated an elevated risk for type 2 diabetes among women receiving antidepressant medication compared with nonusers. It was the top story in endocrinology last week.

A cohort of French women currently taking any antidepressant medication were more likely to develop type 2 diabetes during 6 years of follow-up compared with nonusers, independent of severe depressive symptoms.

Japanese adults may be at greater risk for type 2 diabetes if they take antidepressants, but high HbA1c can be addressed by taking a lower dose or discontinuing the drugs, according to findings published in Diabetes Care.

Patients receiving buprenorphine for treatment of opioid use disorder were more likely to use medications for unrelated, chronic conditions like depression, a study published in Medical Care revealed.